Antiviral activity of stachyflin on influenza A viruses of different hemagglutinin subtypes

Virology Journal

Hiroshi Kida¹  Ryu Yoshida²  Kimihito Ito¹  Naoki Yamamoto³  Yoshihiro Sakoda³  Takeshi Noshi²  Masatoshi Okamatsu³  Manabu Igarashi¹  Yurie Motohashi³ 

[1] Division of Bioinformatics, Research Center for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan;Discovery Research Laboratories, Shionogi & Co., Ltd., Settsu, Osaka 566-0022, Japan;Department of Disease Control, Laboratory of Microbiology, Graduate School of Veterinary Medicine, Hokkaido University, Kita-18 Nishi-9, Sapporo 060-0818, Japan

关键词: Docking model;    HA inhibitor;    Anti-influenza drug;    Stachyflin;   

Others  :  1150799
DOI  :  10.1186/1743-422X-10-118

 received in 2012-11-28, accepted in 2013-04-11,  发布年份 2013

【 摘 要 】

Background

The hemagglutinin (HA) of influenza viruses is a possible target for antiviral drugs because of its key roles in the initiation of infection. Although it was found that a natural compound, Stachyflin, inhibited the growth of H1 and H2 but not H3 influenza viruses in MDCK cells, inhibitory activity of the compound has not been assessed against H4-H16 influenza viruses and the precise mechanism of inhibition has not been clarified.

Methods

Inhibitory activity of Stachyflin against H4-H16 influenza viruses, as well as H1-H3 viruses was examined in MDCK cells. To identify factors responsible for the susceptibility of the viruses to this compound, Stachyflin-resistant viruses were selected in MDCK cells and used for computer docking simulation.

Results

It was found that in addition to antiviral activity of Stachyflin against influenza viruses of H1 and H2 subtypes, it inhibited replication of viruses of H5 and H6 subtypes, as well as A(H1N1)pdm09 virus in MDCK cells. Stachyflin also inhibited the virus growth in the lungs of mice infected with A/WSN/1933 (H1N1) and A/chicken/Ibaraki/1/2005 (H5N2). Substitution of amino acid residues was found on the HA2 subunit of Stachyflin-resistant viruses. Docking simulation indicated that D37, K51, T107, and K121 are responsible for construction of the cavity for the binding of the compound. In addition, 3-dimensional structure of the cavity of the HA of Stachyflin-susceptible virus strains was different from that of insusceptible virus strains.

Conclusion

Antiviral activity of Stachyflin was found against A(H1N1)pdm09, H5, and H6 viruses, and identified a potential binding pocket for Stachyflin on the HA. The present results should provide us with useful information for the development of HA inhibitors with more effective and broader spectrum.

【 授权许可】

   
2013 Motohashi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH: The molecular basis of the specific anti-influenza action of Amantadine. EMBO J 1985, 4:3021-3024.
• [2]Moscona A: Medical management of influenza infection. Annu Rev Med 2008, 59:397-413.
• [3]Pinto LH, Holsinger LJ, Lamb RA: Influenza virus M2 protein has ion channel activity. Cell 1992, 69:517-528.
• [4]Palese P, Tobita K, Ueda M, Compans RW: Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61:397-410.
• [5]Gubareva LV, Kaiser L, Hayden FG: Influenza virus neuraminidase inhibitors. Lancet 2000, 355:827-835.
• [6]Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Frederick GH, Sugaya N, Kawaoka Y: Resistant influenza a viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
• [7]Shental-Bechor D, Danieli T, Henis Y, Ben-Tal N: Long-range effects on the binding of the influenza HA to receptors are mediated by changes in the stability of a metastable HA conformation. Biochim Biophys Acta 2002, 1565:81-89.
• [8]Feng F, Miura N, Isoda N, Sakoda Y, Okamatsu M, Kida H, Nishimura S: Novel trivalent anti-influenza reagent. Bioorg Med Chem Lett 2010, 20:3772-3776.
• [9]O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR: Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 2003, 47:2518-2525.
• [10]Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R, Krystal M: Molecular mechanism underlying the action of a novel fusion inhibitor of influenza a virus. J Virol 1997, 71:4062-4070.
• [11]Vanderlinden E, Göktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, Cesur N, Naesens L: Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J Virol 2010, 84:4277-4288.
• [12]Plotch SJ, O'Hara B, Morin J, Palant O, LaRocque J, Bloom JD, Lang SA Jr, DiGrandi MJ, Bradley M, Nilakantan R, Gluzman Y: Inhibition of influenza a virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 1999, 73:140-151.
• [13]Yoshimoto J, Kakui M, Iwasaki H, Fujiwara T, Sugimoto H, Hattori N: Identification of a novel HA conformational change inhibitor of human influenza virus. Arch Virol 1999, 144:865-878.
• [14]Yoshimoto J, Kakui M, Iwasaki H, Sugimoto H, Fujiwara T, Hattori N: Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor, stachyflin. Microbiol Immunol 2000, 44:677-685.
• [15]Yagi S, Ono J, Yoshimoto J, Sugita K, Hattori N, Fujioka T, Fujiwara T, Sugimoto H, Hirano K, Hashimoto N: Development of anti-influenza virus drugs I: improvement of oral absorption and in vivo anti-influenza activity of stachyflin and its derivatives. Pharm Res 1999, 16:1041-1046.
• [16]Yoshimoto J, Yagi S, Ono J, Sugita K, Hattori N, Fujita T, Fujiwara T, Sugimoto H, Hashimoto N: Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives. J Pharm Pharmacol 2000, 52:1247-1255.
• [17]Kida H, Webster RG, Yanagawa R: Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of a/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol 1983, 76:91-99.
• [18]Yanagita H, Yamamoto N, Fuji H, Liu X, Ogata M, Yokota M, Takaku H, Hasegawa H, Odagiri T, Tashiro M, Hoshino T: Mechanism of drug resistance of hemagglutinin of influenza virus and potent scaffolds inhibiting its function. ACS Chem Biol 2012, 7:552-562.
• [19]Russell RJ, Kerry PS, Stevens DJ, Steinhauer DA, Martin SR, Gamblin SJ, Skehel JJ: Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA 2008, 105:17736-17741.
• [20]Liu S, Li R, Zhang R, Chan CC, Xi B, Zhu Z, Yang J, Poon VK, Zhou J, Chen M: CL-385319 inhibits H5N1 avian influenza a virus infection by blocking viral entry. Eur J Pharmacol 2011, 660:460-467.
• [21]Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG: Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 2009, 53:3088-3096.
• [22]Rachakonda PS, Veit M, Korte T, Ludwig K, Böttcher C, Huang Q, Schmidt MF, Herrmann A: The relevance of salt bridges for the stability of the influenza virus hemagglutinin. FASEB J 2007, 21:995-1002.
• [23]Mueller DS, Kampmann T, Yennamalli R, Young PR, Kobe B, Mark AE: Histidine protonation and the activation of viral fusion proteins. Biochem Soc Trans 2008, 36:43-45.
• [24]Drake JW, Holland JJ: Mutation rates among RNA viruses. Proc Natl Acad Sci USA 1999, 96:13910-13913.
• [25]Minagawa K, Kouzuki S, Tani H, Ishii K, Tanimoto T, Terui Y, Kamigauchi T: Novel stachyflin derivatives from stachybotrys sp. RF-7260. Fermentation, isolation, structure elucidation and biological activities. J Antibiot (Tokyo) 2002, 55:239-248.
• [26]Tobita K: Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol 1975, 162:23-27.
• [27]Reed LJ, Muench H: A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.
• [28]Skehel JJ, Hay AJ: Nucleotide sequences at the 5’ termini of influenza virus RNAs and their transcripts. Nucleic Acids Res 1978, 5:1207-1219.
• [29]Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y: "Ambisense" approach for the generation of influenza a virus: vRNA and mRNA synthesis from one template. Virology 2000, 267:310-317.
• [30]Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG: A DNA transfection system for generation of influenza a virus from eight plasmids. Proc Natl Acad Sci USA 2000, 97:6108-6113.
• [31]Manzoor R, Sakoda Y, Nomura N, Tsuda Y, Ozaki H, Okamatsu M, Kida H: PB2 Protein of a highly pathogenic avian influenza virus strain a/chicken/Yamaguchi/7/2004 (H5N1) determines its replication potential in pigs. J Virol 2009, 83:1572-1578.
• [32]Tsuda Y, Isoda N, Sakoda Y, Kida H: Factors responsible for plaque formation of a/duck/Siberia/272/1998 (H13N6) influenza virus on MDCK cells. Virus Res 2009, 140:194-198.
• [33]Eswar N, John B, Mirkovic N, Fiser A, Ilyin VA, Pieper U, Stuart AC, Marti-Renom MA, Madhusudhan MS, Yerkovich B, Sali A: Tools for comparative protein structure modeling and analysis. Nucleic Acids Res 2003, 31:3375-3380.
• [34]Shen MY, Sali A: Statistical potential for assessment and prediction of protein structures. Protein Sci 2006, 15:2507-2524.
• [35]Laskowsk RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993, 26:283-291.
• [36]Eisenberg D, Lüthy R, Bowie JU: VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol 1997, 277:396-404.
• [37]Thomsen R, Christensen MH: MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006, 49:3315-3321.